8′-chloro-5′-(2-hydroxyethoxy)-2′,3′-dihydro-1′H-spiro[cyclohexane-1,4′-quinazoline]-2′-one | 460346-28-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 8′-chloro-5′-(2-hydroxyethoxy)-2′,3′-dihydro-1′H-spiro[cyclohexane-1,4′-quinazoline]-2′-one
• 英文别名: 8'-chloro-5'-(2-hydroxyethoxy)-1'H-spiro[cyclohexane-1,4'-quinazolin]-2'(3'H)-one；8-Chloro-5-(2-hydroxyethoxy)spiro[1,3-dihydroquinazoline-4,1'-cyclohexane]-2-one
• CAS: 460346-28-5
• 化学式: C₁₅H₁₉ClN₂O₃
• 分子量: 310.78
• InChiKey: JMCCOEJBVQAXPU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  70.6
• 氢给体数：
  3
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  8′-chloro-5′-(2-hydroxyethoxy)-2′,3′-dihydro-1′H-spiro[cyclohexane-1,4′-quinazoline]-2′-one 在 三乙胺 作用下， 以 二氯甲烷 、 乙腈 为溶剂， 生成 Ethyl 2-[2-(8-chloro-2-oxospiro[1,3-dihydroquinazoline-4,1'-cyclohexane]-5-yl)oxyethylamino]acetate
  参考文献：
  名称：

  Spiroquinazolinones as novel, potent, and selective PDE7 inhibitors. Part 2: Optimization of 5,8-disubstituted derivatives

  摘要：

  The optimization of 5,8-disubstituted spirocyclohexane-quinazolinones into potent, selective, soluble PDE7 inhibitors with acceptable in vivo pharmacokinetic parameters is presented. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.07.010
• 作为产物：
  描述：

  1-(2-chloro-5-methoxyphenyl)urea 在 盐酸 、 PPA 、 三溴化硼 、 potassium carbonate 作用下， 以 四氢呋喃 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 生成 8′-chloro-5′-(2-hydroxyethoxy)-2′,3′-dihydro-1′H-spiro[cyclohexane-1,4′-quinazoline]-2′-one
  参考文献：
  名称：

  Spiroquinazolinones as novel, potent, and selective PDE7 inhibitors. Part 2: Optimization of 5,8-disubstituted derivatives

  摘要：

  The optimization of 5,8-disubstituted spirocyclohexane-quinazolinones into potent, selective, soluble PDE7 inhibitors with acceptable in vivo pharmacokinetic parameters is presented. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.07.010

文献信息

• New spirocondensed quinazolinones and their use as phosphodiesterase inhibitors
  申请人：Warner-Lambert Company LLC

  公开号：EP1400244A1

  公开（公告）日：2004-03-24

  The invention relates to compounds of formula (I) wherein R1, R2 and m are as defined in the description, their use as medicament, pharmaceutical compositions containing them and a process for their preparation. These compounds act as Phosphodiesterase inhibitors and inhibit in particular PDE-7.

  本发明涉及式（I）中R1、R2和m的化合物，其中R1、R2和m的定义如描述中所定义，它们作为药物的用途，含有它们的药物组合物以及它们的制备方法。这些化合物作为磷酸二酯酶抑制剂，特别是抑制PDE-7。
• Spirocondensed quinazolinones and their use as phosphodiesterase inhibitors
  申请人：——

  公开号：US20040106631A1

  公开（公告）日：2004-06-03

  The invention relates to compounds of formula (I) 1 wherein R 1 , R 2 and m are as defined in the description, their use as medicament, pharmaceutical compositions containing them and a process for their preparation.

  本发明涉及式(I)1的化合物，其中R1、R2和m如描述中定义的，它们的用途作为药物、含有它们的制药组合物以及它们的制备方法。
• Treatment of Addiction and Impulse-Control Disorders Using PDE7 Inhibitors
  申请人：OMEROS CORPORATION

  公开号：US20130267502A1

  公开（公告）日：2013-10-10

  This disclosure is directed to treatment of addictions and primary impulse-control disorders using phosphodiesterase 7 (PDE7) inhibitors, alone or in combination with other therapeutic agents.

  本公开涉及使用磷酸二酯酶7（PDE7）抑制剂，单独或与其他治疗药物联合治疗成瘾和原发性冲动控制障碍。
• Use of PDE7 Inhibitors for the Treatment of Movement Disorders
  申请人：OMEROS CORPORATION

  公开号：US20140179717A1

  公开（公告）日：2014-06-26

  A method of treating a movement abnormality associated with the pathology of a neurological movement disorder, such as Parkinson's disease or Restless Leg(s) Syndrome by administering a therapeutically effective amount of a PDE7 inhibitory agent. An aspect of the invention provides for the administration of a PDE& inhibitory agent in conjunction with a dopamine agonist or precursor, such as levodopa. In another aspect of the invention, the PDE7 inhibitory agent may be selective for PDE7 relative to other molecular targets (i) known to be involved with the pathology of Parkinson's disease or (ii) at which other drug(s) that are therapeutically effective to treat Parkinson's disease act.

  一种治疗神经运动障碍病理学相关的运动异常的方法，例如帕金森病或不宁腿综合症，通过给予治疗有效量的PDE7抑制剂。该发明的一个方面是在给予多巴胺激动剂或前体（如左旋多巴）的同时给予PDE7抑制剂。在该发明的另一个方面，PDE7抑制剂可以相对于其他分子靶点（i）已知与帕金森病的病理学有关或（ii）其他治疗帕金森病有效的药物作用的靶点而选择性地作用于PDE7。
• USE OF PDE7 INHIBITORS FOR THE TREATMENT OF MOVEMENT DISORDERS
  申请人：Omeros Corporation

  公开号：US20160015715A1

  公开（公告）日：2016-01-21

  A method of treating a movement abnormality associated with the pathology of a neurological movement disorder, such as Parkinson's disease or Restless Leg(s) Syndrome by administering a therapeutically effective amount of a PDE7 inhibitory agent. An aspect of the invention provides for the administration of a PDE& inhibitory agent in conjunction with a dopamine agonist or precursor, such as levodopa. In another aspect of the invention, the PDE7 inhibitory agent may be selective for PDE7 relative to other molecular targets (i) known to be involved with the pathology of Parkinson's disease or (ii) at which other drug(s) that are therapeutically effective to treat Parkinson's disease act.

  本发明涉及一种治疗神经运动障碍病理学相关的运动异常的方法，例如帕金森病或不宁腿综合症，通过给予治疗有效量的PDE7抑制剂。本发明的一个方面提供了与多巴胺激动剂或前体（例如左旋多巴）一起给予PDE7抑制剂的治疗方法。在本发明的另一个方面，PDE7抑制剂可以选择性地作用于PDE7，而相对于其他分子靶点（i）已知与帕金森病的病理学有关或（ii）其他治疗帕金森病的药物作用的靶点。